U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...
Investor's Business Daily on MSN
Dow Jones futures: Stocks rise on Micron, inflation, but don't do this; Nike, Fed earnings late
Among growth ETFs, the Innovator IBD 50 ETFFFTY bounced 1.9%. The iShares Expanded Tech-Software Sector ETFIGV gained 1.4%, ...
The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...
13don MSN
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, and Bristol Myers in focus
Get the latest stock market and healthcare sector updates, top gainers and losers, and key regulatory news impacting investments.
Major stock indexes surged Thursday after delayed Consumer Price Index data came in better than expected, with the blue-chip ...
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.
2don MSN
Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market.
Three stocks that did well during the last big bear market in 2022 are AbbVie ( ABBV +0.15%), Eli Lilly ( LLY +2.09%), and Chevron ( CVX 1.32%). Here's why they could potentially be good investments ...
Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable ...
Wall Street rose to more records even as a sell-off for Oracle and worries about a potential bubble in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback